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ABSTRACT   
“Bioavailability” is defined as the rate and extent of drug absorption. Any 
alteration in drug bioavailability is reflected in its pharmacologic effects. To attain the 
desired therapeutic objective, the drug has to be delivered at an optimal rate and 
amount. Three major approaches to enhance bioavailability are the Pharmaceutic 
approach, the Pharmacokinetic approach and the Biological approach [1]. The 
Pharmacokinetic and Biologic approaches involve alteration in chemical structure and 
route of administration respectively. Both these approaches have drawbacks such as 
repetition of clinical trials, regulatory approvals and lower patient compliance 
respectively. Hence the Pharmaceutic approach which involves modification of the 
formulation, manufacturing process or physicochemical properties of drug without 
changing the chemical structure, is the most preferred approach to enhance 
bioavailability. The attempts are mainly aimed at enhancing rate of dissolution of drug 
as it is the rate limiting step in absorption of most drugs.   
The therapeutic effectiveness of the drug depends on the ability of the dosage 
form to deliver the drug to its site of action at a rate and amount sufficient to elicit 
desired therapeutic response. An oral drug delivery system providing a uniform drug 
release can only partly satisfy the therapeutic and biopharmaceutical needs, as it does 
not take in to account site specific absorption rates within the gastrointestinal tract. For 
oral therapeutic use this means the creation of dosage form delivering the drug during 
its gastrointestinal transit at the right time and at right site at therapeutically optimal rate 
[2]. This implies 1) delivering locally effective drugs like antibiotics, anti inflammatory 
or cytostatic agents only at their target site and 2) releasing drugs such as Digoxin, 
Ampicillin, Ciprofloxacin and Cefuroxime axetil which have a limited absorption 
window at the preferred absorption site. To attain the desired therapeutic effectiveness 
without altering drug bioavailability, the design and evaluation of delivery systems for 
gastrointestinal tract requires the knowledge of three inter-related topics, the drug, the 
delivery system and the destination intended [3].  
The primary concern for drugs exhibiting lower bioavailability and restricted 
absorption window is designing the delivery systems which release the drug at the 
desired site thus enhancing their absorption  and in turn the bioavailability. To achieve 
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this goal, spatial and temporal release formulations have been developed in the past [4, 
5]. Polymers play an important role in the design of these advanced drug products. A 
major consideration in use of polymers for drug delivery is drug-polymer interaction, 
drug transformation and its degradation [6]. The drug-excipient interactions often 
modify the physicochemical characteristics of the drug [7] and sometimes these result in 
complete loss of activity of drug or delayed release. 
In the present work we have identified drugs which have limited absorption 
window, which in turn affects their absorption and consequently bioavailability. Also 
we identified drugs which were inactivated due to the drug-polymer interaction 
adversely affecting their bioavailability. In particular, drugs such as Cefuroxime axetil, 
Ciprofloxacin HCl and Clarithromycin which are absorbed in upper gastric region and 
those required for local and immediate action were selected.  
The complexity of the molecule Cefuroxime axetil poses a great challenge to 
formulation scientist to administer it without alteration of bioavailability. Cefuroxime 
axetil has a limited absorption window restricted to upper gastric region as it is 
hydrolyzed by esterase enzyme in intestine to Cefuroxime, a form, which cannot be 
absorbed orally [8, 9]. Bioavailability of orally administered CA is low (37-52 %) [10]. 
It is therefore essential that the drug be released in gastric region under acidic pH 
conditions so that its bioavailability is not further affected. Extensive efforts have been 
made in the past to taste mask it using Cellulose acetate trimellitate (CAT), 
Hydroxypropyl methylcellulose phthalate (HPMCP) and Eudragit E (EE). Cefuroxime 
axetil was completely degraded in the presence of the Eudragit E and led to 
unacceptably high proportions of impurities in presence of CAT [11,12]. Ciprofloxacin 
HCL is a bitter drug better absorbed from gastric region, but is associated with 
extremely bitter taste. It is highly water soluble and hence requires a coating which is 
completely impermeable to water. Eudragit E is soluble below pH 5 and permeable 
above it so it cannot be used. To overcome this it has been coated with enteric polymers 
to mask the bitter taste. However this affects its absorption in the gastric region. 
The limitations of the existing polymers described above, have restricted the 
formulation development of taste masked products of these drugs. This has educed the 
need to develop a polymer which is capable of catering to these formulation needs.  
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To overcome the above limitations we undertook the development of a new 
reverse enteric polymer (NREP) which dissolves at gastric pH and can be used for the 
development of drug delivery systems for taste masking, immediate and sustained 
gastric release. We undertook detailed investigation of the polymers for 
physicochemical characteristics and their adaptability to pharmaceutical process. We 
also undertook evaluation of biological reactivity (in-vitro and in-vivo) to ensure 
biocompatibility. A detailed investigation of drug-polymer compatibility to ensure 
availability of the drug in active form was undertaken. We evaluated the blends of 
NREP with other polymers to bring about sustained release of these drugs at gastric and 
intestinal pH. The extent of interaction between polymer blends was quantified in terms 
of Schneider equation. The in-vitro drug release experiments were carried out to ensure 
the complete release of drugs. For all the drugs investigated the in-vitro and in-vivo 
correlation is well established. The in-vitro release of drugs therefore provides a good 
measure for ensuring the absorption of drugs.  
NREP was found to effectively taste mask the drugs with immediate release in 
gastric pH. Also sustained release formulation for gastric release of drugs can be 
formulated using NREP. This ensured the release of drugs better absorbed from gastric 
region at the right site and at the rate desired.  
The work is presented in ten chapters and a brief outline of each is given below. 
  
Chapter 1: Introduction and motivation   
This is an introductory chapter where the problems arising in formulating drugs 
with complex pharmacokinetic and physicochemical properties resulting in 
compromising with bioavailability are discussed. Various pharmaceutical compositions 
aimed at achieving one formulation attribute (eg taste masking) compromising on the 
release and bioavailability were analyzed. The restrictions faced by formulation 
scientists due to non availability of polymer with specific functionality leading to 
constraints imposed on formulation development are described. One of the areas where 
the polymers are most extensively used is the taste masking of the drugs. The gastric 
soluble polymer Eudragit E is most commonly used for the taste masking of the drugs. 
However certain drugs like cefuroxime axetil, indomethacin and warfarin are reported 
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to interact with Eudragit E resulting in either complete deactivation or delayed release 
of drug. In addition, there may also be issues that must be addressed relative to region-
specific absorption. 
The polymers widely used for taste masking include the enteric polymers like 
cellulose acetate phthalate, hydroxymethyl cellulose phthalate, cellulose trimellitate, 
hydroxymethyl cellulose acetate succinate, shellac and polymethacrylates like Eudragit 
L and S. However the use of these polymers delays the release of the drug till they reach 
the intestine where the polymers are soluble. This causes a delay in the release of the 
drugs due to the design of the delivery system based on such enteric polymers which 
cannot release drugs having limited absorption window restricted to the upper GI tract. 
This adversely affects the bioavailability of the drugs. This literature survey reveals that 
a clear understanding and consideration of these issues in the design and execution of a 
successful development program for bioavailability enhancement in taste masked 
products is lacking. It also highlights the need to identify and synthesize new polymers 
that can overcome the above mentioned limitations. Based on the summary of the 
literature we identified new polymer compositions, which could be explored for these 
applications. We further validated their utility by investigating the drug-polymer 
interactions by various tools such as FTIR, NMR, HPLC and DSC and drug release 
studies.  
 
Chapter 2: Objective and scope of work  
The major focus of this work is to design and evaluate new reverse enteric 
polymer for the development of taste masked, immediate and sustained gastric release 
product. The polymer and formulation development is aimed to provide the site specific 
delivery of drugs with restricted absorption window to gastric region to enable better 
absorption and ensure bioavailability without deactivation of the drug. This chapter 
highlights the major objectives and also the scope of entire work and these are;  
1. To identify the reverse enteric polymer capable of taste masking drugs like 
Cefuroxime axetil without its inactivation.  
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2. To develop reverse enteric polymer which is insoluble and exhibits negligible 
swelling at higher pH to enable development of taste masked products of 
highly water soluble drugs like Ciprofloxacin HCl.  
3. To undertake synthesis and physicochemical characterization of polymer to 
meet the above requirements. Characterize polymers for solubility / swelling at 
different pH. Optimize polymer composition to yield stringent pH dependent 
behavior (solubility < pH 4 and insoluble above it). Evaluate the effect of 
polymer structure on Tg and biocompatibility.    
4. To encapsulate the drugs and evaluate rapid release of drugs at gastric pH 
where they are better absorbed thereby ensuring the bioavailability. 
Encapsulate Cefuroxime axetil, Ciprofloxacin HCL and Clarithromycin by 
various techniques and undertake drug release studies at both gastric and near 
neutral pH. 
5.   To investigate drug polymer interaction to establish that the drug is being 
retained in biologically active form, by techniques such as DSC, FTIR, NMR 
and HPLC analysis. 
6. To evaluate blends of new reverse enteric polymer with enteric and pH 
dependent polymers for miscibility for attaining sustained gastric release 
useful for drugs better absorbed from upper gastric region. Evaluate polymer 
blend miscibility by FTIR and Thermal analysis and quantify the extent of 
interaction in terms of Schneider equation. Investigate the utility of the blends 
in the sustained release of Cefuroxime axetil at gastric pH.  
7. To evaluate hydrophobic blends of new reverse enteric polymer with fatty 
acids to attain rapid release at gastric pH with taste masking ability. 
Investigate the effect of encapsulation of drugs by these blends using 
emulsification solvent evaporation technique, hot melt granulation and spray 
drying on drug release at gastric pH. 
8. To evaluate the effect of polymer molecular weight on polymorphism 
inhibition of Cefuroxime axetil and Celecoxib thereby ensuring their 
bioavailability. Evaluate drug-polymer co-precipitates by XRD. 
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Chapter 3: A new reverse enteric polymer for immediate gastric release: design 
and evaluation  
The major focus of this work was to design and evaluate a new reverse enteric 
polymer which dissolves at pH < 4 and does not swell or dissolve in water and at higher 
pH and pH of saliva so that it can be used to formulate drugs like Cefuroxime axetil and 
Ciprofloxacin HCl. The polymer would be evaluated for its ability to taste mask these 
drugs without their inactivation and release rapidly in stomach where they are better 
absorbed. Various copolymers based on the hydrophobic and basic monomer and ter-
polymers containing a hydrophilic monomer in addition to hydrophobic and basic 
monomer were synthesized. The influence of monomer choice and composition on 
dissolution behavior of the films at pH 1.2, 4.5 and 5.8 was investigated. The monomer 
composition was optimized to yield the stringent requirements of pH dependent 
dissolution behavior of polymer. The polymer compositions yielding solubility at pH < 
4 were obtained by polymerizing methyl methacrylate (MMA), 2-hydroxy ethyl methyl 
methacrylate (HEMA) and 4-vinyl pyridine (4-VP). The influence of monomer choice 
and composition on Tg and biocompatibility is discussed. The physicochemical 
characteristics of the polymer were determined by NMR, FTIR, GPC and DSC. The 
details of polymer synthesis are discussed in patent application (M.G. Kulkarni and 
A.R. Menjoge, US 20050137372, 23 June 2005).  
NREP was found to be suitable for the pharmaceutical applications and 
evaluation of in-vitro and in-vivo biological reactivity as per USP 26 NF XXI (2003) 
indicated that the polymer was non-toxic and can be used for further investigation.  
 
Chapter 4: Taste masked compositions comprising NREP & bitter drugs: 
enhancing bioavailability with rapid gastric release 
This chapter discloses the use of NREP for coating the drugs to attain taste 
masking and with rapid dissolution at gastric pH to enable rapid absorption of drugs. 
Bitter drugs Cefuroxime axetil (CA), Ciprofloxacin HCl and Clarithromycin were 
coated using NREP. The coating was done using emulsification solvent evaporation and 
spray drying technique. CA was released rapidly at gastric pH. The release was 
inhibited at salivary pH. NREP prevented CA leaching in aqueous media. The 
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palatability of the reconstituted CA suspensions was evaluated on the basis of numerical 
grading by the volunteers. The mean grading for the reconstituted taste masked CA 
microspheres was compared with market product Ceftum. The CA compositions based 
on NREP showed a lower release at pH 4.4 and retained the palatability over seven 
days. The volunteers graded the formulations between 0-2 and rated the formulations as 
palatable. The taste of the reconstituted microspheres was better than the market 
formulation Ceftum initially for a period of 3 days and was comparable thereafter.  
Taste masked Ciprofloxacin and Clarithromycin microparticles were evaluated 
for the drug release at acidic pH. These drugs were released rapidly under gastric 
conditions. The polymer can be used for taste masking of variety of drugs in different 
dosage forms. The details of taste masked compositions are discussed in patent 
application (M.G. Kulkarni and A.R. Menjoge, US 20050136114, 23 June 2005).  
 
Chapter 5: Drug polymer compatibility studies: implications for bioavailability of 
drugs   
This chapter provides a detailed investigation on drug-polymer interactions. 
Inactivation of Cefuroxime axetil by Eudragit E is reported in the past. The inactivation 
of Cefuroxime axetil in the presence of Eudragit E was investigated as a reference. The 
influence of polymer composition on drug inactivation was investigated. The 
dimethylamino group of Eudragit E interacts with Cefuroxime axetil resulting in 
carboxylate salt formation. This causes its inactivation. These studies provided useful 
insights in evaluating the interactions between NREP synthesized by us and Cefuroxime 
axetil. A detailed investigation of physicochemical interactions between Cefuroxime 
axetil and NREP by DSC, FTIR, NMR and HPLC analysis is presented. The self 
associations between NREP and its lower basicity prevent the interaction between 
NREP and Cefuroxime axetil. The acetoxy ethyl group in cefuroxime axetil is not 
cleaved by NREP. These investigations were of paramount importance as they establish 
the usefulness of NREP in development of taste masked formulation of CA without 
causing its inactivation or degradation. 
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 Chapter 6: Miscible blends of new reverse enteric polymer with enteric and pH 
independent polymers for sustained gastric release  
This chapter describes the evaluation of miscible blends of NREP with enteric 
and pH independent polymers to attain sustained gastric release of Cefuroxime axetil. 
Cefuroxime axetil has a short half life (2 hr), so sustained release formulations are 
desirable (13). However its gelling tendency in presence of moisture and the limited 
absorption window make it difficult to attain sustained release. Further, blends of 
reverse enteric polymer with enteric polymers result in insoluble polyelectrolyte 
complexes and hence cannot be used in film coatings. The novelty of our work is that it 
provides a new set of polymer blends containing reverse enteric and enteric polymers 
capable of film forming which can be investigated for tailoring varied drug release 
patterns. The nature of interactions between blend constituents was established by 
analyzing FTIR spectra of blends. The extent of interaction has been investigated by 
thermal analysis and quantified in terms parameters K1 and K2 derived from the third 
power Schneider equation. Based on these values, the interactions between NREP and 
these polymers have been ranked in the order Zein < Ethylcellulose < Eudragit S < 
Eudragit L < Hydroxypropyl methylcellulose phthalate < Cellulose acetate phthalate. 
These investigations help interpret the drug release pattern from the blends based on the 
extent of interactions. The results of the mechanistic investigations provided a more 
rational approach to tailor polymer blends for drug release. The utility of the blends in 
sustained release of Cefuroxime axetil under gastric conditions over 3 hrs has been 
established. The details of polymer blends for drug delivery are discussed in patent 
application (A.R. Menjoge and M.G. Kulkarni, US 20050281874, Dec 2005). 
 
Chapter 7: Mechanistic investigations contributing to the miscibility of NREP with 
enteric polymers  
This chapter provides insights to achieve controlled hydrogen bonding in 
polymer-polymer blends to attain the desired extent of interactions needed to ensure 
miscibility without complexation. These investigations provided a rational basis to 
understand the miscibility in NREP-polymer blends and also led to a new set of 
polymer blends, which were subsequently investigated to achieve the desired release 
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rate. The structural attributes of NREP, which contribute to miscibility without 
complexation as seen in Eudragit E have been explained. A detailed investigation of the 
interactions between Eudragit E with enteric and pH independent polymers was 
undertaken. The effect of basicity, spacer length and structural defects provided an in 
depth knowledge on polymer structure affecting the extent of miscibility. The 
investigations reveal that miscible blends result as the extent of interaction between 
immiscible polymer blend increases. Further increase in interaction leads to 
complexation.  
 
Chapter 8: Blends of NREP with fatty acids for enhancing drug release at gastric 
pH  
This chapter describes the use of blends of fatty acids with NREP to enhance the 
release from the fatty acid based compositions. Fatty acids are largely investigated for 
taste masking applications. Fatty acids like stearic acid release the drug upon formation 
of soluble sodium salt in intestinal region. This restricts their application for drugs 
absorbed from gastric region. The blends of NREP with fatty acids provide gastric 
release of drugs. These formulations are highly hydrophobic and hence are very 
effective for taste masking. Pharmaceutical compositions containing Cefuroxime axetil 
and Ciprofloxacin using NREP-fatty acid blends were investigated for drug release at 
gastric pH. The formulations were made by emulsification solvent evaporation 
technique, spray drying and holt melt granulations. The advantage of using these 
formulations is that gastric release for both Cefuroxime axetil and Ciprofloxacin HCL is 
attained due to dissolution of NREP. The details of these blends for drug delivery are 
discussed in patent application (A.R. Menjoge and M.G. Kulkarni, PCT/IN04/ 00379).  
    
Chapter 9:  Enhancement of bioavailability by polymorphism inhibition  
This chapter describes the polymer (NREP) attributes which inhibit conversion 
of amorphous Cefuroxime axetil to crystalline form. Certain drugs exist as polymorphs 
or are more bioavailable in an anhydrous or amorphous form and which pose the 
stability problems fall under this category. Therefore, stability of the drug from 
moisture and conversion from an unstable form to a stable form and moisture 
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permeability assessment and release enhancement efforts for the drug as an initial step 
in development of dosage form is often warranted. Cefuroxime axetil is more 
bioavailable in the amorphous form. The co-precipitation of Cefuroxime axetil and 
Celecoxib with low molecular weight polymer results in its crystallization at lower 
polymer loading. The high molecular weight NREP polymers were found to retain 
Cefuroxime axetil and Celecoxib in amorphous form thereby ensuring the 
bioavailability of these drugs. Further NREP is hydrophobic so it warrants the moisture 
protection of these drugs. The details of polymorphism inhibition are discussed in 
patent application (M.G. Kulkarni and A.R. Menjoge, US 20050136115, 23 June 2005).    
    
Chapter 10: Conclusions and suggestions for future work  
The important conclusions arrived at from the work are discussed in this 
chapter. Briefly these can be summarized as follows;  
1. The polymer architecture affects the physiochemical properties like pH dependent 
behavior, glass transition temperature and the nature of its interactions. The choice of 
4-vinyl pyridine as basic monomer contributes to acid solubility.    
2.  The charge density on the NREP, basicity of the 4-vinyl pyridine and self associations 
reduce the drug-polymer interactions between NREP and Cefuroxime axetil avoiding 
its degradation and inactivation thus ensuring drug release in biologically active form.  
3. The encapsulation of Cefuroxime axetil by NREP thus provides site specific delivery 
for enhanced absorption with taste masking. Similarly other drugs like Ciprofloxacin 
HCl and Clarithromycin can be taste masked and released at the desired site.  
4. It was demonstrated that blends of NREP with enteric polymers are capable of film 
coating. This provided a new set of polymer blends which can be further tailored to 
attain sustained gastric and intestinal release. These blends were found to be useful to 
attain sustained gastric release of Cefuroxime axetil. 
 5.  High molecular weight NREP was found to be effective in polymorphism inhibition.   
   NREP prevented the conversion of highly bioavailable amorphous form of 
Cefuroxime axetil into crystalline thereby retaining its bioavailability.  
6. The self associations in NREP enhance the glass transition temperature making the   
polymer adaptable to pharmaceutical processes involving heat and enable ease of 
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storage. The self associations and charge density on the polymer suppress its 
biological reactivity, eliminating any adverse biological response rendering the 
polymer biocompatible.  
This chapter also gives insights for the future scope of the work. Certain drugs 
exhibit interactions with anionic polymers resulting in delayed release. This is not 
desired as these drugs are expected to be released in the intestine. Since NREP is 
polybase its blending with enteric polymers can prevent the interactions between enteric 
polymers and cationic drugs. These assumptions need to be validated. 
The use of NREP as a barrier coating material to protect the moisture sensitive 
drug needs to be evaluated. Normally seal coat with polymers such as shellac and ethyl 
cellulose is used to protect many of the moisture sensitive drugs. Apart from this, 
special packaging materials are used to restrict the moisture permeation. However the 
use enteric polymers or water resistant polymers, retards the release of the drug. NREP 
is hydrophobic in nature and its utility for such applications can be investigated.     
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